Skip to main content
69 search results for:

Sulfasalazine 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 26-08-2020 | Psoriatic arthritis | News | Article

    Better drug retention in PsA patients with methotrexate than sulfasalazine

    A retrospective cohort study suggests significantly higher retention with methotrexate monotherapy than sulfasalazine in DMARD-naïve patients with psoriatic arthritis.

  2. 17-09-2018 | Rheumatoid arthritis | Article

    Low persistence rates in rheumatoid arthritis patients treated with triple therapy are attributed to adverse drug events associated with sulfasalazine

    Erhardt DP et al.  Arthritis Care Res (Hoboken)  2018. doi: 10.1002/acr.23759

  3. 07-12-2022 | Rheumatoid arthritis | News | Article

    Similar reduction in CV risk with different add-on RA treatments

    Among patients with active rheumatoid arthritis, adding tumor necrosis factor inhibitors to methotrexate is associated with a similar reduction in vascular inflammation to that seen with add-on sulfasalazine plus hydroxychloroquine, suggest findings from a randomized controlled trial.

  4. 19-08-2022 | Rheumatoid arthritis | News | Article

    Caution needed with hydroxychloroquine use in older RA patients with heart failure

    Kim et al point out that “a potential cardioprotective activity of methotrexate” could explain their findings, so they conducted an exploratory sensitivity analysis comparing hydroxychloroquine with sulfasalazine in 5018 matched patient pairs.

  5. 06-06-2022 | EULAR 2022 | Conference coverage | Article

    DMARD treatment has ‘profound anticoagulant effects’ in early RA

    Bas Dijkshoorn (Amsterdam Rheumatology and Immunology Center, the Netherlands) and colleagues analyzed data from 24 Dutch patients who participated in NORD-STAR , a randomized trial comparing conventional treatment (n=5; either prednisolone or sulfasalazine combined with hydroxychloroquine and intra-articular corticosteroids) with certolizumab pegol (n=6), abatacept (n=7), or tocilizumab (n=6), all given alongside methotrexate, in patients with newly diagnosed RA.

  6. 01-02-2022 | Rheumatoid arthritis | News | Article

    DMARD use does not impact Parkinson’s disease risk in RA

    As reported in Neurology , there was no significant association between the use of sulfasalazine, methotrexate, gold preparations, immunosuppressants, or corticosteroids before the 3-year lag period and the risk for PD.

  7. 01-03-2021 | COVID-19 | Feature | Article

    COVID-19 vaccination in patients with rheumatic diseases

    For many of the drugs – including TNF inhibitors, interleukin inhibitors, low-dose glucocorticoids (prednisone-equivalent dose <20 mg/day), sulfasalazine, hydroxychloroquine, and leflunomide – no modifications to either immunomodulatory therapy or vaccination timing are recommended.

  8. 20-09-2021 | Rheumatoid arthritis | News | Article

    Recurrent RA joint swelling tends to affect same joints each time

    The study compared four different treat-to-target strategies (sequential monotherapy; step-up combination therapy starting with methotrexate; initial combination therapy with methotrexate, sulfasalazine, and prednisone; and initial combination therapy with methotrexate and infliximab), assessing swelling in 68 joints every 3 months for a median of 10 years.

  9. 24-10-2017 | Rheumatoid arthritis | Editorial | Article

    Demise of the triple

    Triple therapy, the combination of methotrexate (MTX), sulfasalazine (SSZ), and hydroxychloroquine (HCQ), appears to be effective in selective patients with rheumatoid arthritis (RA).

  10. 04-02-2021 | COVID-19 | News | Article

    Disease activity linked to COVID-19 mortality risk in rheumatology patients

    “Future studies should address the observed association of rituximab and sulfasalazine with poor outcomes,” they add.

  11. 11-11-2020 | ACR 2020 | Conference coverage | Article

    Survey sheds light on rheumatology provider experiences during COVID-19 pandemic

    In terms of medication and vaccination, Singh noted that 45% of participants reported a shortage in hydroxychloroquine and 15% reported and shortage in interleukin (IL)-6 inhibitors, and the majority said they would not withhold hydroxychloroquine (95%) or sulfasalazine (74%) treatment for a live COVID-19 vaccine.

  12. 11-09-2020 | Rheumatoid arthritis | News | Article

    ‘Gaps in knowledge’ on DMARD use and fertility in RA patients highlighted

    De Cock and team say that one study evaluated the association between sulfasalazine and fertility in the preconception phase, finding no significant association between use of the agent and a TTP of more than 1 year.

  13. 08-07-2020 | Rheumatoid arthritis | News | Article

    SELECT-EARLY: Better RA outcomes with upadacitinib vs methotrexate

    Less than 10% of participants had previously taken methotrexate, while around a quarter had received other conventional DMARDs, primarily sulfasalazine or hydroxychloroquine. van Vollenhoven and colleagues report that ACR50 response rates at week 12 – the primary endpoint requested by the US FDA – were significantly higher among patients in the upadacitinib 15 mg and 30 mg groups compared with the methotrexate arm, at 52% and 56% versus 28%, respectively.

  14. 13-11-2019 | Rheumatoid arthritis | ACR/ARP 2019 | Article

    Methotrexate plus glucocorticoids compare favorably with biologics in early RA

    In addition to this, 200 patients were randomly assigned to receive the active conventional treatment regimen, which comprised either oral prednisone (20 mg tapered to 5 mg in 9 weeks) or sulfasalazine (2 g/day), hydroxychloroquine (35 mg/kg per week), and mandatory intra-articular triamcinolone hexacetonide in up to four swollen joints (≤80 mg/visit up to week 20).

  15. 08-06-2020 | EULAR 2020 | Conference coverage | Article

    Methotrexate unlikely to exacerbate risk for ILD in RA patients

    Patients taking methotrexate were no more likely to develop ILD as those not taking methotrexate and the same was true for patients taking sulfasalazine prescriptions versus those who were not.

  16. 10-11-2019 | Rheumatoid arthritis | ACR/ARP 2019 | Article

    Systematic use of ultrasound not beneficial for treatment targeting in RA patients

    All the patients were treated using the same DMARD escalation program, starting with methotrexate, then combination treatment with methotrexate/sulfasalazine/hydroxychloroquine, and finally a biologic DMARD.

  17. 05-06-2020 | EULAR 2020 | Conference coverage | Article

    Adding csDMARD improves TNF inhibitor retention in axSPA

    He said this was “somewhat in relation to the use of methotrexate,” which was also higher in the combination group in these countries, compared with countries with above average retention rates, where sulfasalazine was used more frequently.

  18. 06-04-2018 | Spondyloarthropathies | Feature | Article
    Updated April 2021

    At a glance: Trials of tofacitinib in spondyloarthritis

    OPAL Broaden: PsA Phase 3 Patient population: Active PsA and an inadequate response to conventional DMARDs Treatment groups: Tofacitinib 5 mg or 10 mg twice daily, adalimumab, or placebo, all given alongside a stable dose of a single conventional DMARD (methotrexate, sulfasalazine, or leflunomide) Status: Published https://clinicaltrials.gov/show/NCT01877668 The findings from OPAL Broaden, published in The New England Journal of Medicine in October 2017, showed that patients treated with tofacitinib 5 mg or 10 mg were significantly more likely to achieve at least a 20% improvement in ACR criteria (ACR20) after 3 months of treatment than placebo-treated patients, with corresponding rates of 50% and 61% versus 33%.

  19. 13-02-2020 | Rheumatoid arthritis | News | Article

    Limited response to first-line etanercept in very early RA

    Those in the methotrexate treat-to-target arm received once-weekly depomedrone 120 mg and methotrexate 15 mg, increasing to 25 mg at 2 weeks, with subsequent addition of sulfasalazine and hydroxychloroquine between weeks 8 and 20, and etanercept at week 24, according to disease activity.

  20. 11-02-2020 | Rheumatoid arthritis | News | Article

    Reduced bone density loss with b/tsDMARDs vs csDMARDs in RA

    The csDMARDs included methotrexate, sulfasalazine, hydroxychloroquine, azathioprine, and leflunomide.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.